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ABSTRACT: This study compares the use of wet milling and indirect ultrasound for promoting nucleation and controlling the
particle size during the continuous crystallization of a hard-to-nucleate active pharmaceutical ingredient (API). Both an immersion
and an external wet mill installed on a recirculation loop were investigated. It was found that all methodologies significantly
improved the nucleation kinetics, and the effects of key process parameters (e.g., mill speed, temperature, and ultrasound intensity)
on particle size were experimentally investigated. A minimum d50 of 27 and 36.8 μm was achieved when using the wet mill and
ultrasound, respectively. The effectiveness of wet milling was demonstrated in a three-stage mixed suspension mixed product
removal continuous crystallization of the API that was operated continuously for 12 h (eight residence times), achieving a steady
state with minimal fouling. Strategies for improving the overall robustness of the setup in routine manufacturing are discussed.
KEYWORDS: wet milling, ultrasound, continuous crystallization, fouling, mixed suspension mixed product removal crystallizer,
crystallization
1. INTRODUCTION
Continuous manufacturing of active pharmaceutical ingre-
dients (APIs) offers an attractive route for producing high-
quality and consistent materials and reducing the time-to-
market of newly discovered drugs. The majority of
pharmaceutical products are delivered through oral solid
dosage forms which require tight control of the crystalline
material in terms of its purity and particle attributes (size and
overall size distribution, shape, and form).1 These attributes
can be controlled from the crystallization unit operation which
is an essential separation and purification technique used in
small-molecule drug substance (DS) manufacturing.2 Con-
tinuous crystallization has gained increasing interest from both
the pharmaceutical industry and regulatory authorities, its
benefits having been demonstrated on several APIs using
different reactor types [e.g., mixed suspension mixed product
removal (MSMPR) and plug flow].3−9 These include steady-
state operation,10 higher yield,11,12 better control over
crystallization mechanisms (supersaturation, nucleation, and
crystal growth),13 enhanced particle attributes (e.g., size
distribution),14 increased heat transfer, and ease of scale-
up.15 The preferred reactor types used to achieve the
aforementioned benefits are single- and multiple-stage
MSMPR crystallizers primarily due to their ability to robustly
handle solids and the flexibility they offer in process design
allowing, for example, the use of readily available stirred tank
reactors both at the lab and pilot scale.16
Crystallization process development involves selection of an
appropriate solvent system,17 a method to generate super-
saturation (e.g., cooling, antisolvent addition, evaporation, or
pH adjustment),18−21 and tuning of process parameters (e.g.,
mixing intensity, cooling profile, antisolvent addition method
and rate, and so forth) to achieve the desired crystal
properties.22,23 However, limited choices with solvent selection
driven by upstream demands (e.g., compatibility with reagents)
often result in difficulty in controlling the interplay of the
various crystallization mechanisms (agglomeration, attrition,
breakage, encrustation, etc.,).24,25 To mitigate these issues,
particularly, where drug product performance-related attributes
(e.g., particle size and shape) cannot be delivered, alternative
particle engineering strategies have been investigated, often
using the application of external fields. Two such examples are
ultrasound and high-shear rotor-stator technologies.
The main interest in applying ultrasound technology is for
inducing nucleation at low supersaturations while manipulating
the particle size and shape.26 This can be achieved through the
application of acoustic energy, resulting in cavitation generated
from a probe horn (sonoprobe) typically placed in direct
contact with the process solution.27 Such an approach poses
some significant limitations, for example, surface erosion
leading to particle shedding and heavy metal contamination
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of the process stream,27,28 substantial temperature deviations
causing particle dissolution29 and potential compound
degradation, rapid dissipation of energy transferred per unit
volume, and excessive noise in the vicinity of the probe leading
to operator health and safety concerns.30 An alternative and
more attractive strategy would be to separate the sonoprobe
from the process solution and use air or some other media to
transfer the acoustic energy to the process medium (herein
referred to as indirect sonication). However, there are few
reports of this mode of application in the literature,31,32 and it
is unknown whether such a configuration can exert sufficient
and consistent power transfer to influence the crystallization
kinetics and particle attributes in a controllable manner.
On the other hand, high-shear rotor-stator wet milling
devices have found widespread use in pharmaceutical
manufacturing owing to their ease of use and broad availability.
They can be applied either immersed into the reactor or
through a recirculation loop to perform size reduction,33−36
shape manipulation,37−39 polymorphic selection,40,41 conglom-
erate separation42 in full-scale manufacturing,43,44 or seed
generation.45,46 In continuous manufacturing, a key driver for
applying wet milling is to control nucleation for APIs
possessing wide metastable zone widths (MSZWs) and thus
exhibiting slow nucleation kinetics. Its use has also been shown
to reduce the process startup and time to reach the steady
state.47 For such APIs, control of nucleation or use of seed is
critical to ensure a robust continuous process, maintain a
steady state, and control encrustation and classification, which
could result from supersaturation buildup and excessive
particle growth resulting from the lack of the available surface
area. While wet milling can be deployed as a continuous seed
generator and potentially remove the need for external
seeding,47 understanding operational challenges such as
process integration, robustness during extended continuous
operation, and the particle size limits achievable remains
unreported.
The API used in this study is discovered at Takeda
Pharmaceuticals. The current crystallization process does not
use seed as there are no known polymorphs and particle size
control is achieved through a subsequent jet-milling process.
The crude API is dissolved in a mixture of 40/60 v/v %
MeOH/H2O (15 vol) at 65 °C, and activated charcoal (3 wt
%) is added to clarify the solution. The suspension is filtered,
and the resulting solution is cooled to 5 °C over 5 h to
crystallize the API. Particles with a typical d50 of around 200
μm are isolated in 90% yield (on an 85 kg scale), which are jet-
milled to a d50 target of 2.5−11.0 μm. The objective of the
work described in this manuscript is to develop a continuous
crystallization process to control the particle size distribution
(PSD) and avoid the additional milling step. Preliminary batch
crystallization experiments suggested that the API exhibited
slow nucleation kinetics but very good growth. Furthermore,
MSZW experiments using Crystal 16 showed that the system
held supersaturation very well (Figure 1a). Initial unseeded
single-stage continuous crystallization experiments resulted in
nucleation on/near the reactor wall, which was 3−5 °C lower
in temperature than the process temperature, which lead to
extreme fouling (Figure 1b) and failure to achieve the steady
state. In order to minimize encrustation, the solvent
composition was switched from 40/60 v/v % MeOH/H2O
to 70/30 v/v % MeOH/H2O, in which the API had a wider
MSZW. It was postulated that a wider MSZW would reduce
the fouling on the reactor walls caused by the temperature
difference between the solution and the walls. However, while
improved, fouling was still observed over time and attempts to
improve nucleation rates by increasing shear through
increasing the MSMPR agitation rates, impeller design (retreat
curve, pitch blade, and Rushton turbine), and material of
construction (PTFE, SS) were unsuccessful. While the
challenges with controlling nucleation could be controlled via
a continuous seeded process, this would add further complex-
ity in terms of process design, management of a separate raw
material source, and obtaining seed of a small-enough particle
size to afford the product with the target PSD (submicron/
micron size seed would be required). Therefore, in situ
strategies were investigated, and the results are described in
this manuscript. Initially, experimental strategies using high
shear wet milling and sonication are introduced where three
different intensified approaches are investigated and the
influence of key processing parameters on nucleation and
particle properties is presented. From analysis of the process
trends and operating conditions, wet milling was selected and
integrated in a three-stage continuous MSMPR system that
was operated for 16 h to produce the API.
2. EXPERIMENTAL SECTION
2.1. General Procedure for Wet Milling Experiments.
Piping and instrumentation diagrams (P&IDs) of a single-stage
Figure 1. (a) Metastable zone for the two different solvent compositions investigated; (b) reactor fouling when the 40/60 v/v % MeOH/H2O
solvent system was used.
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MSMPR setup equipped with both an external wet mill and an
immersion mill are shown in Figure 2.
Two 1 L cylindrical jacketed vessels equipped with an
overhead stirrer, a glass retreat curve impeller (three-blade, 68
mm diameter), temperature probe, and condensers were used
as the feed tank and MSMPR crystallizer. A feedback flow rate
control system based on a Red Lion programmable logic
controller (PLC) and consisting of a gear pump (Ismatec, part
number: ISM895E) and Coriolis flow meter (Bronkhorst, part
number: M13-RGD-11-0-S) was used to transfer the hot
solution (typically maintained at 55 °C) from the feed tank to
the MSMPR. Both the gear pump and Coriolis flow meter
were placed in an enclosed heating box maintained at 65 °C
using an air heat blower (MISUMI, part number: MAHY-
1310) to prevent the feed from crystallizing during the transfer.
For the experiments that used the external wet mill (IKA
magic LAB), the flow rate through the mill was controlled and
monitored using a Masterflex peristaltic pump (Masterflex L/S
equipped with the pump head part number: 77390-00) and
Coriolis flow meter (Bronkhorst, part number: M15-MAD-22-
0-S) installed as part of the external recirculation loop. The
pump was placed between the reactor and the flow meter,
before the wet mill (Figure 2a). However, it was subsequently
removed, as it was demonstrated that, across the ranges
investigated, the flow rate through the wet mill (turnover
number per residence) had only a small impact on the PSD
(Figure 7b). 1/4″ OD PTFE tubing was used that was
insulated with fiberglass to avoid heat loss. The wet mill was
equipped with three fine generators and was heated to 40 °C
using a thermocirculator (Huber Ministat 230).
The slurry transfer was achieved using a 1/4″ OD PTFE dip
tube and pressurizing the MSMPR intermittently to 4 psi using
nitrogen. A Siemens PLC was used to control the nitrogen
valve and ensure that less than 10% of the total volume of the
MSMPR was transferred each time in order to maintain a
periodic steady state.48 This resulted in transfers taking place
every 3 min when the residence time was 30 min. To conserve
the material, the suspension from the MSMPR was recycled
and transferred directly back to the feed tank where it was
dissolved and reused.
In a typical experiment, API (70 g, 152 mmol) and a 70/30
v/v % MeOH/H2O solvent mixture (1 L, 14.3 vol) were
charged to the feed tank and agitated at 250 rpm at 65 °C (10
°C above the saturation temperature) until fully dissolved. The
API (42 g, 91 mmol) was then charged to the MSMPR
crystallizer followed by a 70/30 v/v % MeOH/H2O solvent
mixture (0.6 L, 14.3 vol). The agitation speed was set to 250
rpm, and the suspension in the MSMPR was adjusted to the
desired experimental temperature and maintained at that
temperature for at least 30 min, until stable.
The external wet mill, if used, was switched on and set to the
desired rotational speed. The Masterflex pump was switched
on, and the desired flow rate was set using the Red Lion PLC.
The suspension was recirculated through the mill for a
minimum of 30 min until a constant particle size distribution
was achieved, as indicated by the focused beam reflectance
measurement (FBRM). The feed pump and Siemens PLCs
were then turned on and set to the desired settings to transfer
the feed solution to the MSMPR crystallizer and back to the
feed vessel. The thermocirculator connected to the wet mill
was set to the same temperature as the MSMPR crystallizer.
For the experiments employing an immersion mill, a special
pressure-rated dispersing unit (part number: S25 KV) was
used with the IKA T25 drive to allow for the use of pressure
during the slurry transfer from the MSMPR. As shown in
Figure 2b, in this setup, the overhead agitator was replaced
with the mill, which was found to provide vigorous mixing
across the agitation speeds and fill volumes investigated.
2.2. Three-Stage Continuous MSMPR Experimental
Procedure. The P&ID of the three-stage MSMPR setup is
shown in Figure 3a. One 3 L and three 1 L cylindrical jacketed
vessels equipped with an overhead stirrer, a glass retreat curve
impeller (three-blade, 68 mm diameter), temperature probe,
and condensers were used as the feed tank and MSMPR
crystallizers, respectively. The temperature of each reactor was
independently controlled using a dedicated thermocirculator
(Huber, Ministat 230). The configuration of the feed vessel
and first stage of the MSMPR was identical to that shown in
Figure 2a and described earlier. The only modification was that
the return line from the wet mill to the reactor was heated to
Figure 2. PI&Ds for the single-stage MSMPR/wet mill setup: (a) with an external wet mill and (b) with an immersion mill.
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minimize fouling that was observed during the earlier
optimization experiments.
API (210 g, 455 mmol) and a 70/30 v/v % MeOH/H2O
solvent mixture (3 L, 14.3 vol) were charged to the feed tank
and agitated at 250 rpm at 65 °C (10 °C above the saturation
temperature) until fully dissolved. The API (35 g, 76 mmol)
was then charged to each of the three MSMPR crystallizers
followed by a 70/30 v/v % MeOH/H2O solvent mixture (0.5
L, 14.3 vol). The removal dip pipes were set to maintain the
internal volume of each crystallizer at 0.5 L. The agitation
speed was set to 250 rpm, and each stage was adjusted to the
desired experimental temperature and maintained at that
temperature for at least 30 min, until stable (45, 35, and 5 °C
for stages 1, 2, and 3, respectively).
The external wet mill equipped with three fine rotors was set
to 12,400 rpm. The suspension was recirculated for 30 min
until a constant particle size distribution was achieved, as
indicated by the FBRM. The feed pump and Siemens PLCs
were then turned on and set to 16.67 mL/min to maintain a
total system residence time of 90 min (30 min in each of the
three stages). The thermocirculator connected to the wet mill
was set to 40 °C in order to maintain the temperature of the
stage 1 crystallizer at 45 °C. The product from the third stage
was collected directly on a Buchner funnel, and the feed was
replenished periodically to maintain operation for 12 h.
2.3. General Procedure for Ultrasound Experiments.
All experiments were performed in a 1 L cylindrical jacketed
vessel equipped with an overhead stirrer, glass retreat curve
Figure 3. Three-stage MSMPR setup: (a) P&ID and (b) picture of the setup.
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impeller (three-blade, 68 mm diameter), temperature probe,
condenser, and Mettler-Toledo G-400 FBRM probe (Figures 4
and 5). The ultrasound flow cell (GDmini2, Hielscher, Telt
Germany) was equipped with a glass tube (3.9 mL, ID: 0.15
inch) and connected to the crystallizer using 1/4″ polytetra-
fluoroethylene (PTFE) tubing (Figure 4). J-type thermocou-
ples were installed on the flow-cell inlet and outlet for
temperature monitoring. The flow cell was coupled with a
UP200St-TD transducer (200 W), and pressurized water (8
bar) was used to control its temperature and transfer the
ultrasonic vibrations to the glass tube. The ultrasound was
operated continuously at a frequency of 26 kHz, and power
amplitudes of 20, 40, and 80% were investigated.
A Masterfex peristaltic pump (Masterflex L/S equipped with
pump head 77390-00) was installed between the flow cell and
the 1 L reactor (Figure 5). Stirring was initiated at 250 rpm,
and the API (70 g) was dissolved in a 70/30 v/v % MeOH/
H2O (1 L, 14.3 vol) mixture at 70 °C. Once there were no
solids remaining, as indicated by the G-400 FBRM probe, the
temperature was adjusted to 45 °C, to generate a super-
saturated solution (s = 1.61), and the Masterflex pump
followed by the ultrasound transducer was initiated at the
desired settings.
2.4. Laser Diffraction Particle Size Method. A Malvern
Mastersizer 2000 instrument equipped with a wet dispersion
unit and Hydro Sight was used for all laser diffraction particle
size analyses. Standard instrument settings were as follows:
Mie evaluation mode, a product refractive index setting of 1.52,
a dispersant refractive index of 1.38, a dispersion unit speed of
1500 rpm, a saturated solution of API in 2-propanol was used
as the dispersant, a sample measurement time of 10 s, a 5−15%
obscuration limit, and 30% sonication were used. A total of
three measurement cycles were performed, and the average
value was reported.
Approximately, 10 mL of the slurry was removed from the
crystallizer using a transfer pipette whose tip was cut. The solid
sample was isolated by filtration and dried in a vacuum oven at
45 °C for overnight before the measurement. The dry powder
was dispersed in saturated 2-propanol and added dropwise to
the wet dispersion unit to give the desired obscuration,
typically around 7%.
2.5. HPLC Method. The high-performance liquid chroma-
tography (HPLC) method used for concentration measure-
ment and for analyzing the purity of the final product
employed a symmetry C 18.5 μm 4.5 × 75 mm column,
maintained at 25 °C, and was run on an Agilent 1100 Series. A
0.1% formic acid in H2O solution was used as mobile phase A,
and a 0.1% formic acid in CH3CN solution was used as mobile
phase B. The total flow rate was set to 1.0 mL/min, the
injection volume was 5.0 μL, and the detection was carried out
at 230 nm. The total method analysis time was 10 min. A
gradient was used starting at 90% of mobile phase A, moving to
60% after 5 min, and ending back up at 90% at 6 min. The
latter composition was maintained for 1 min after which time
the eluent was switched to 100% mobile phase B for 4 min.
Finally, the column was re-equilibrated at 100% mobile phase
A for a total of 4 min.
The sample preparation procedure was as follows: (1) for
concentration analysis, approximately 1 mL of the slurry was
removed from the crystallizer using a syringe and filtered
through a 0.2 μm syringe filter into a preweighed 50 mL
volumetric flask. The resultant mother liquor was diluted with
a CH3CN/H2O (50/50 v/v %) mixture to 50 mL; (2) for
purity analysis, 25 mg of API was dissolved in a 25 mL
volumetric flask using 70/30 v/v % MeOH/H2O. API was
eluted at approximately 4.2 min.
2.6. Sampling Protocol. Regular sampling was imple-
mented throughout the duration of each experiment. For
concentration analysis, slurry samples (5 mL) were directly
withdrawn from the vessel and immediately filtered via a
syringe filter (0.2 μm) into a preweighed volumetric flask (25
mL). The relevant diluents for HPLC measurement were then
used (Section 2.5). For each sampling time, triplicates were
taken for a consistency check. For particle size distribution
analysis, 25−50 mL (depending on slurry density) was directly
withdrawn from the vessel using a transfer pipette and
immediately filtered via vacuum filtration, washed with the
same solvent composition used for the crystallization, and
Figure 4. P&ID of the ultrasound flow cell.
Figure 5. Ultrasound experimental setup.
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dried in a vacuum oven overnight (40−45 °C). Dried samples
were then further subjected for microscopic and particle size
analysis.
3. RESULTS AND DISCUSSION
3.1. Use of Wet Milling to Control Nucleation. In order
to address the issues observed with the poor nucleation
kinetics of API, resulting in washout and extreme fouling, wet
milling was investigated both as part of an external
recirculation loop and directly installed within the first stage
of a cascade of continuous stirred reactors. A proof-of-concept
single-stage crystallization using the former configuration and
an IKA MagicLab wet mill was successfully conducted and
operated for a total of 10 residence times (τ) without any
fouling. An undersaturated solution of API (70 mg/mL) in 70/
30 v/v % MeOH/H2O at 65 °C was fed to the crystallizer that
was operated at 45 °C with the wet mill running at 10,000 rpm.
At this temperature, if the system fully desupersaturated,
approximately 36% of the product was expected to crystallize,
as the solubility of API at 45 °C is 44.5 mg/mL. This is typical
in the design of a three-stage MSMPR process, where the
amount of material deposited in each stage is divided equally
across the total number of reactors used. The residence time
was set to 30 min, while the turnover number per residence
(TOPRT) time, which is defined as the number of times the
slurry is recycled through the wet mill during one residence
time, was 15. The TOPRT can be calculated from the recycle
volumetric flow rate through the wet mill and the volumetric








where V is the MSMPR operating volume, τ is the MSMPR
residence time, and qmill is the recycle volumetric flow rate
through the wet mill.
The system startup was achieved by charging 35 g of API to
the crystallizer followed by 0.6 L of a 70/30 v/v % MeOH/
H2O mixture. The jacket temperature of the crystallizer was set
to 45 °C. The wet mill was then initiated and operated at the
Figure 6. a) Concentration and (b) PSD results as a function of residence time for a one-stage continuous crystallization experiment operated at 45
°C with a 30 min residence time and an external wet mill set at 10,000 rpm with a TOPRT of 15.
Organic Process Research & Development pubs.acs.org/OPRD Article
https://doi.org/10.1021/acs.oprd.1c00209
Org. Process Res. Dev. 2021, 25, 2119−2132
2124
desired setting until the PSD of the suspension was
equilibrated, typically 30 min, after which time the feed
pump was switched on. At 10,000 rpm and using the wet mill
configured with the three fine rotors, the d50 of the product at
the end of the equilibration period was 45 μm. This defined
the smallest PSD that could be obtained through crystal
breakage. As can be seen from Figure 6, the crystallizer’s
concentration rapidly reached the steady state (within 2τ) and
was operated at a relatively low supersaturation of 1.12. It is
worth mentioning that at τ = 0, the concentration was below
the compound’s solubility at 45 °C. This is because the
temperature in the crystallizer was lower than 45 °C due to the
cooling jacket of the wet mill. Once the hot feed started to
pump in, the temperature in the crystallizer was well controlled
to 45 °C. The particle size distribution took a total of 4τ to
reach the steady state and stabilized at a d50 of 32 μm,
approximately 20% smaller than the initial PSD, presumably as
a result of shear-induced secondary nucleation. The slight
upward inflection in d50 and d90 above 6τ is within the
measurement error. Therefore, all subsequent experiments
were run for a total of 8τ to ensure the steady state. It was
found that the use of the FBRM and UV or mid FT-IR to
monitor in real time chord length distributions and
concentration, respectively, during the continuous experiments
was unreliable due to fouling of the probes. As a result, samples
were removed every 2τ for offline concentration and PSD
analysis to confirm the steady state.
Four parameters were investigated in an attempt to
minimize the product particle size and the supersaturation
within the crystallizer in order to control encrustation: reactor
temperature (T), TOPRT, milling speed, and τ (Figure 7).
The optimization was conducted in a one-variable-at-a-time
(OVAT) study and started with the investigation of the impact
of the crystallizer temperature and therefore crystallization
driving force. The milling speed, TOPRT, and residence time
of the MSMPR were set at 10,000 rpm, 15, and 30 min,
respectively, and a total of three temperatures were
investigated, 50, 45, and 40 °C. These corresponded to
equilibrium concentrations of 56.0, 44.5, and 35.2 mg/mL,
respectively, that would result in 20, 36, and 50%, respectively,
Figure 7. Optimization of the single-stage MSMPR equipped with the IKA magicLAB wet mill: (a) impact of the crystallizer T on steady-state
concentration and PSD (wet mill rpm = 10,000, τ = 30 min, and TOPRT = 15); (b) impact of TOPRT on steady-state concentration and PSD
(wet mill rpm = 10,000, τ = 30 min, and T = 45 °C); (c) impact of wet mill rotational speed on steady-state concentration and PSD (τ = 30 min,
TOPRT = 15, and T = 45 °C); and (d) impact of the crystallizer τ on steady-state concentration and PSD (wet mill rpm = 12,400 and Τ = 45 °C).
Organic Process Research & Development pubs.acs.org/OPRD Article
https://doi.org/10.1021/acs.oprd.1c00209
Org. Process Res. Dev. 2021, 25, 2119−2132
2125
of the product being crystallized assuming full desupersatura-
tion. The results from these experiments are outlined in Figure
7a. As expected, the steady-state supersaturation increased
from 1.05 to 1.15 as the T decreased from 50 to 40 °C, and
more solute is available for crystal growth and/or nucleation.
The particle size at the steady state, as indicated by the d50,
dropped significantly from 48 to 32 μm as the temperature was
reduced from 50 to 45 °C. This is most likely a result of the
higher supersaturation at 45 °C, resulting in more secondary
nucleation during the crystallization. Interestingly, no signifi-
cant change in steady state d50 was observed when the
temperature decreased from 45 to 40 °C, which is probably
because the reduction on particle size reached the limit of the
wet mill. As our objective was to generate the smallest possible
particle size material while balancing steady-state super-
saturation in order to mitigate encrustation, an operating T
of 45 °C was selected.
TOPRT was varied from 7.5 to 22.5 to investigate its impact
on steady-state PSD and supersaturation. When the MSMPR τ
was set to 30 min, this TOPRT range corresponded to
adjusting the flow rate through the wet mill from 150 to 400
mL/min. The milling speed and crystallizer T were fixed at
10,000 rpm and 45 °C, respectively, and the results of this
study are shown in Figure 7b. It was found that a slightly
smaller PSD was obtained at the lower TOPRT (d50 of 31 vs
35 μm for a TOPRT of 7.5 vs 22.5) that could be a result of
the longer residence time within the wet mill, resulting in
increased breakage and/or secondary nucleation. Based on
these data, it would also appear that the τ in the mill had a
larger effect on particle size than the overall turn-over number
of the crystallizer. Nevertheless, over the investigated range,
the TOPRT had a negligible impact on both the steady-state
PSD and supersaturation. This suggests that the values for
TOPRT used in our experiment were in the attrition regime,
where particles have already been reduced by chipping and
further milling results in no significant size reduction.49,50
Next, the impact of the wet mill rotational speed was
investigated focusing on higher speeds in an attempt to obtain
Figure 8. Comparison of startup modes for a one-stage continuous crystallization experiment operated at 45 °C with a 90 min residence time and
an immersion mill set at 10,000 rpm: (a,b) PSD as a function of τ for a startup from a saturated suspension and (c,d) PSD as a function of τ for a
startup from a batch crystallization.
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smaller PSD materials and further reduce steady-state super-
saturation through increased secondary nucleation. While the
wet mill is capable of operating at a maximum speed of 26,000
rpm, control of the crystallizer temperature became increas-
ingly challenging beyond 15,000 rpm, requiring a significant
temperature drop across the vessel jacket. Therefore, the
maximum rotational speed was restricted to 15,000 rpm. The
TOPRT, crystallizer T, and τ were 15, 45 °C and 30 min,
respectively. As can be seen from Figure 7c, milling speed only
affected the particle size of the product, affording a d50 of 27.6
μm when 15,000 rpm was used versus 32.8 μm at 10,000 rpm.
However, temperature control became challenging even at a
milling speed of 15,000 rpm. The jacket temperature of the wet
mill needs to be set lower than 5 °C, which could result in
fouling and blockage over extended run times. Therefore,
12,400 rpm was selected as the optimal speed.
Finally, the effect of τ of the MSMPR was studied, with the
maximum time limited to 90 min, primarily driven by a desire
to maintain a reasonable productivity for the process. Since the
TOPRT is dependent on τ, fixing it would require adjusting,
for each experiment, the flow rate of the recirculation loop
through the mill. As it was earlier demonstrated that TOPRT
had a small impact on PSD across the range investigated
(<10%), the pump before the wet mill that restricted flow
through the mill was removed, so that the recirculation rate
was determined by the mill rotational speed, which was around
900 mL/min when 12,400 rpm was used. This corresponded
to a TOPRT range of 45−135 across the τ investigated.
Furthermore, in earlier experiments, some fouling of the return
loop from the wet mill to the MSMPR was observed that could
result in blockage upon prolonged operation. Therefore, that
section of the recirculation loop was heated 5 °C above the
crystallizer temperature, that is, to 50 °C. The experimental
results are shown in Figure 7d, and as expected, they show that
steady-state supersaturation decreases with increasing τ as the
system is given more time to desupersaturate. Interestingly, the
supersaturation is overall much higher in this set of
experiments (e.g., when τ = 30 min and s = 1.23 vs 1.12
without the heated return loop), which could be attributed to
dissolution of the generated fines, as a result of the heated
return loop. For this set of experiments, the τ through the wet
mill was constant and an overall longer crystallizer τ effectively
resulted in a higher turn-over number and therefore a lower
particle size (27.3 μm when τ = 90 min).
However, there was a concern about the robustness of the
external wet mill over prolonged operation during manufactur-
ing particularly with regard to potential leaks as seals degraded,
managing the temperature drop across the recirculation loop
and the numerous surfaces available for nucleation that could
lead to encrustation and ultimately blockage. Therefore, the
use of an immersion mill was evaluated that was placed directly
within the crystallizer and replaced the overhead agitator. The
mill was used both to agitate the reactor contents and to
control nucleation and particle size.
Startup from a batch crystallization was found to be more
effective than from a saturated suspension, affording a tighter
PSD and allowing the system to reach the steady state within 4
versus 6 τ (Figure 8). Accordingly, 35 g of API was charged to
the crystallizer followed by 0.5 L of a 70/30 v/v % MeOH/
H2O mixture. The mill was switched on to the desired setting
(10,000 rpm), and the resulting slurry was heated to 60 °C
until all solids were fully dissolved. The solution was then
cooled to 45 °C, at which point an undersaturated solution of
API (70 mg/mL) in 70/30 v/v % MeOH/H2O at 65 °C was
fed to the crystallizer at 16.67 mL/min, corresponding to a τ of
30 min. This afforded a steady-state d50 of 52 μm and a
supersaturation of 1.18. The mill rotational speed and
crystallizer τ were then optimized through a series of OVAT
studies (Figure 9). The range of speeds investigated was
8000−12,000 rpm, as at lower speeds, solids were not fully
suspended and at higher ones, control of the reactor
temperature became extremely challenging. As expected, the
higher the mill speed, the lower the steady state particle size
(54 vs 47 μm at 10,000 vs 12,000 rpm). The impact on the
supersaturation was minimal and varied from 1.19 to 1.15
(Figure 8a). A slightly wider residence time range than that
investigated with the external wet mill was explored (30−120
min) and found to have the largest impact on both the steady-
state supersaturation and particle size. These ranged between
1.15 and 1.06 and 49−30 μm, respectively, with higher τ
Figure 9. Optimization of the single-stage MSMPR equipped with an immersion mill: (a) impact of mill rotational speed on steady-state
concentration and PSD (τ = 30 min and T = 45 °C) and (b) impact of the crystallizer τ on steady-state concentration and PSD (mill rpm = 12,000
and Τ = 45 °C).
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affording smaller particle sizes and lower supersaturations as
the system is given more time to desupersaturate and the mill
TOPRT is higher. Overall, it was found that both mills were
capable of maintaining similar levels of supersaturation within
the crystallizers and afforded similar particle sizes. Most
importantly, both systems were able to maintain the steady
state and minimize encrustation by effectively controlling
nucleation. However, it did not prove possible to generate
particle sizes of <30 μm under these conditions.
3.2. Use of Sonication to Control Nucleation.
Sonication was next investigated as a means of controlling
nucleation and potentially generating a smaller particle size
material than could be obtained through a mechanical mill. A
flow cell (GDmini2, Hielscher, Germany) was used consisting
of a resonating stainless-steel jacket around a glass tube that
was connected to the crystallizer using PTFE tubing (Figure
4). The flow cell was coupled with a UP200St-TD transducer
(200 W), and temperature-controlled pressurized water was
used as a coolant and to transfer the ultrasonic vibrations to
the glass tube and therefore sonicate the liquid flowing through
the tube. This resulted in a more uniform transfer of power
across the process stream. The coolant also allowed for
accurate control of the process temperature, enabling the
continuous operation of the transducer, in contrast to
immersion probes that can often only be used intermittently
to avoid uncontrolled heating. Furthermore, in this config-
uration, the probe did not come into direct contact with the
process stream, avoiding any potential contamination from
degradation of the probe. It was also anticipated that this setup
could afford a much more robust solution for controlling
nucleation, as it was unobstructed with no moving parts and
the ultrasound could prevent encrustation within the
nucleation device.
The effectiveness of this device as a nucleator at different
amplitudes was evaluated by measuring induction times. The
flow cell was installed on a recirculation loop attached to a 1 L
crystallizer equipped with an FBRM probe. A supersaturated
solution (s = 1.61) of API in 70/30 v/v % MeOH/H2O at 45
°C was recirculated at 300 mL/min in the absence of
ultrasound for 0.5−1 h to allow for the temperature to
stabilize and to confirm the absence of primary nucleation.
After this initial period, the desired ultrasound power
amplitude was selected and applied in the continuous mode
throughout the duration of each experiment.
Indirect sonication had a considerable impact on induction
time (Figure 10). Increasing the power amplitude from 0 to
80% (239.97 kW/m2) reduced the mean induction time from
180 to 5 ± 5.51 min (Figure 10b). Selecting the highest power
Figure 10. Evolution of total count profiles (a) and induction time for API (b) as a function of ultrasound power.
Figure 11. Impact of ultrasound amplitude on particle size (a) and desupersaturation rate (b) over the course of isothermal API crystallization
experiments using an external ultrasound flow cell.
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amplitude of 80% (239.97 kW/m2) produced an instantaneous
occurrence of nucleation within 5 min of ultrasound start
(Figure 10b). This generated a rapid increase in total counts
from 0 to 50 min due to enhanced secondary nucleation which
leveled off after 200 min as the supersaturation is depleted
(Figure 10a).
The initial strategy was to operate in a continuous single-
pass mode without recirculation by feeding an undersaturated
solution (70 mg/mL) through the ultrasound flow cell at
different temperatures and hence supersaturations (35, 40, and
45 °C corresponding to supersaturation values of 2.6, 2, and
1.6, respectively). This would allow for the flow cell to be
positioned between the feed tank and the first stage of a
multistage MSMPR crystallizer effectively separating nuclea-
tion from growth. Based on the induction time measurements,
the transducer would need to be operated at the maximum
amplitude. Initial testing was successful in inducing nucleation
with short τs (11−55 s), but there were significant challenges
with the onset of fouling in the transfer lines as a result of the
extremely low flow rates required to achieve the target τ values
(4−20 mL/min). Furthermore, as a result of the API’s fast
growth kinetics, significant growth was observed, producing
large particles that as a result of the low flow velocities
sedimented in the lines leading to blockage. This approach was
therefore not feasible and efforts were directed toward
incorporating the flow cell in a recirculation loop, in a similar
configuration to that used with the external wet mill.
Isothermal batch experiments were conducted during which
a 70 mg/mL solution of API was prepared in 70/30 v/v %
MeOH/H2O at 60 °C, which was then cooled to 45 °C to
generate a supersaturated solution (s = 1.61). This solution
was recirculated through the flow cell at 300 mL/min
investigating different ultrasound amplitudes (0, 20, and
80%). The particle size and desupersaturation data for these
experiments are shown in Figure 11. A significant particle size
reduction was achieved when an 80% amplitude was used,
affording a d50 of 36.80 μm versus 71.07 and 91.28 μm when
20% or no ultrasound was applied, respectively. Deagglomera-
tion of the particles was observed, and the elongated rod-
shaped particles became more circular (Figure 12a−c). The
concentration profiles obtained for the 20 and 80% ultrasound
conditions show a rapid decline within 25 turnovers, after
which a slow decrease from 25 to 125 turnovers is observed
(Figure 11b). For 80%, overall depletion of concentration was
considerably quicker than 20% which approached the solubility
limit at 40 mg/mL, indicating complete desupersaturation.
This was expected as 80% had a shorter mean induction time
than 20% and therefore faster nucleation kinetics. As the
experiments were conducted under isothermal conditions,
supersaturation consumption is preceded by the rapid
nucleation burst at 80% due to the creation of a large available
Figure 12. Impact of ultrasound amplitude for the following conditions: (a) recycle control, (b) 20, and (c) 80% over the course of isothermal API
crystallization experiments using an external ultrasound flow cell.
Figure 13. Time course particle size (a) and concentration data (b) of each of the three stages for the continuous 12 h MSMPR crystallization
experiment.
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crystal surface area for subsequent growth and supersaturation
depletion.
While promising results from using the sonication method
were observed, the particle size limit achieved was 36.80 μm.
This was comparable with the single-stage MSMPR wet milling
experiments which had reached sizes of ∼30 μm. Although
targeting smaller size ranges of 2−11 μm proved challenging,
both techniques demonstrated the capability to reduce the
nucleation onset for API and the potential to be deployed as
nucleator devices. However, when compared to the application
of high-shear rotor-stator devices in pharmaceutical manufac-
turing, the indirect sonication approach remains at low
technology readiness levels. Further work is therefore required
to better understand the fundamental performance of the
system as a controllable, robust external field generator and
address operational challenges such as scale-up, continuous
running, and performance with different compounds. There-
fore, the development of the continuous MSMPR crystallizer
proceeded with wet milling incorporated within the first stage.
3.3. Development of a Three-Stage MSMPR Crystal-
lization Process. A continuous crystallization experiment was
performed in order to assess the robustness of using the
external wet mill to control nucleation. A three-stage
configuration was selected to provide the system with enough
residence time and temperature drop (from 60 to 5 °C),
required to maintain a reasonable productivity, while
maintaining low steady-state supersaturations to manage
fouling. The optimal operating parameters for stage 1 were
determined through the OVAT experiments described earlier
in the manuscript and consisted of a process temperature of 45
°C and a wet mill rotational speed of 12,400 rpm. The
temperature of the second stage was set at 30 °C, while that of
the third stage was set at 5 °C. All three stages operated at a τ
of 30 min, resulting in a total system τ of 90 min. The system
was initiated from suspensions, and the process was
successfully operated for more than 12 h without blockages
(corresponding to eight residence times). The PSD and
concentration evolution in each stage are presented in Figure
13. The PSD of the first stage reached the steady state in 2 h,
while that of the second and third stages achieved the steady
state after 3 and 4 h (Figure 13a), respectively. The steady
state d50 was 32, 49, and 60 μm for the first, second, and third
stage, respectively. The concentration in each stage stabilized
in less than 3 h. The steady-state concentration in each stage
was 54.8, 32.9, and 16.2 mg/mL, respectively, which
corresponded to supersaturation values of 1.14, 1.45, and
2.75 (Figure 13b). The yield of this continuous run was 77%
w/w. The second and third stage, in particular, operated at
relatively high supersaturation, indicating that longer residence
times would be required to improve efficiency. Some fouling in
the transfer lines was observed that necessitated them being
manually cleaned every two residence times (3 h) to avoid
blockage. This was achieved by alternating between two sets of
lines that were cleaned in between use. Post transfer, it was
impossible to blow the lines dry and any residual liquid
gradually nucleated as the lines were not heated. Heated
transfer lines are critical for maintaining control in this context,
and an automated way of cleaning the lines would be
beneficial. The flow rate through the wet mill gradually
dropped from about 900 to 645 mL/min, indicating some
degree of fouling. This indicated that in order to run for longer
durations, two wet mills may be required configured with
external cleaning loops and a feedback control system to
trigger a cleaning cycle when flow rates drop below a certain
level. Finally, even though the fouling on the reactor walls was
minimal during the 12 h run, a control strategy for its
management is required. It can be envisioned that oscillating
the jacket temperature would result in brief elevated reactor
wall temperatures that may be sufficient to dissolve any nuclei
that may have deposited on them and ultimately manage
fouling.51
4. CONCLUSIONS
A particle engineering strategy for providing control over the
final particle size distribution and overcoming the challenges to
fouling and encrustation during continuous crystallization
development has been investigated for the API.
The API was prone to slow nucleation behavior while
exhibiting fast growth kinetics. By introducing high shear wet
milling and indirect sonication through similar intensified
strategies, both techniques were found to rapidly initiate the
onset and provide good control over nucleation and fouling.
This was experimentally evaluated through the effect of a
number of key processing parameters (supersaturation,
temperature, mill rotational speed, ultrasound power output,
and number of turnovers) on product attributes (size and size
distribution), where the target was to generate small sizes for
seeding purposes. This proved challenging as the size limit
achieved from both strategies ranged from 28 to 37 μm.
However, and equally importantly, well-controlled seeds were
generated without the need for an offline milling step and
fouling was mitigated allowing for the development of a
continuous MSMPR process. The high shear wet mill was
pursued over sonication as the in situ seeding route and this
technology were demonstrated in running a three-stage
MSMPR crystallization process. Finally, areas of improvement
to the overall process design were identified that if optimized
would allow for robust operation over a prolonged duration
suitable for pharmaceutical manufacturing applications.
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This article published ASAP on September 1, 2021. Figure 3a
has been updated and the corrected version was reposted on
September 8, 2021.
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